We are live on ! Find out more
TLIS

Talis Biomedical Corporation Common Stock
TLIS

Delisted

TLIS was delisted on the 30th of August, 2024.

Back to rankings

2 hedge funds and large institutions have $460K invested in Talis Biomedical Corporation Common Stock in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% less funds holding

Funds holding: 18 → 2 (-16)

93% less capital invested

Capital invested by funds: $6.84M → $460K (-$6.38M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 16

Holders
2
Holders Change
-16
Holders Change %
-88.89%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
+$1.4M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$4.4M
2
DCM
DME Capital Management
New York
-$1.29M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$269K
4
PCM
Prelude Capital Management
New York
-$129K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$123K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
BML Capital Management
Indiana
$460K +$1.4M +205,959 +482%
SPIA
2
Steward Partners Investment Advisory
New York
$272 – – –
BBA
3
Baker Bros. Advisors
New York
– -$4.4M -508,323 Closed
DCM
4
DME Capital Management
New York
– -$1.29M -149,052 Closed
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$269K -31,013 Closed
PCM
6
Prelude Capital Management
New York
– -$129K -14,928 Closed
Geode Capital Management
7
Geode Capital Management
Massachusetts
– -$123K -14,020 Closed
Renaissance Technologies
8
Renaissance Technologies
New York
– -$107K -12,299 Closed
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
– -$102K -11,607 Closed
BlackRock
10
BlackRock
New York
– -$37K -4,271 Closed
TRCT
11
Tower Research Capital (TRC)
New York
– -$7.6K -877 Closed
Morgan Stanley
12
Morgan Stanley
New York
– -$754 -87 Closed
Osaic Holdings
13
Osaic Holdings
Arizona
– -$727 -84 Closed
LFG
14
Larson Financial Group
Missouri
– -$121 -14 Closed
Bank of America
15
Bank of America
North Carolina
– -$113 -13 Closed
UBS Group
16
UBS Group
Switzerland
– -$95 -11 Closed
JP Morgan Chase
17
JP Morgan Chase
New York
– -$26 -3 Closed
Qube Research & Technologies (QRT)
18
Qube Research & Technologies (QRT)
United Kingdom
– -$18 -2 Closed

TLIS Hedge Fund Activity: Q3 2024 in Review

2 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q3 2024, worth a combined $460K — down 93% from $6.84M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of TLIS and 0 opened new positions — a net loss of 16 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was BML Capital Management, adding an estimated $1.4M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.4M sold.

  • 2 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q3 2024, down from 18 in Q2 2024.
  • Funds reported $460K of Talis Biomedical Corporation Common Stock stock for Q3 2024, down 93% quarter-over-quarter.
  • 0 funds opened new Talis Biomedical Corporation Common Stock positions in Q3 2024 and 16 closed out, a net change of -16 holders.
  • The largest Talis Biomedical Corporation Common Stock buyer in Q3 2024 was BML Capital Management, an estimated $1.4M added.
  • The largest Talis Biomedical Corporation Common Stock seller in Q3 2024 was Baker Bros. Advisors, an estimated $4.4M sold.

Based on aggregated 13F filings for Q3 2024.